Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Schering-Plough/Novartis's combination drug (indacaterol/mometasone) will edge out AstraZeneca's Symbicort (available in Europe) as the clinical gold standard by 2015. According to the new report entitled In a Highly Competitive Market, Differentiation is Possible: An Asthma Study, the once-daily dosing of indacaterol/mometasone sets it apart from Symbicort, which will launch in the United States this year to much anticipation. Upon its U.S. launch, Symbicort will be the only competitor in that market to GlaxoSmithKline's Advair.

"Although indacaterol/mometasone matches Symbicort on all measures of efficacy and safety, indacaterol/mometasone has a superior delivery profile owing to its once-daily dosing," said Vickie Lai, analyst at Decision Resources. "Physicians value this delivery improvement greatly because it increases patient compliance. Among thought leaders, patient compliance is of paramount importance because consistent administration of anti-inflammatory drugs reduces disease severity and the need for costly healthcare."

About In a Highly Competitive Market, Differentiation is Possible: An Asthma Study

In a Highly Competitive Market, Differentiation is Possible: An Asthma Study covers the current and future state of the asthma drug market. The report includes:

  -- More than 3,000 physician responses that define drug attributes that      drive prescription now and in the future.      -- Clinical end point tradeoffs that are most influential to         physicians.      -- Areas of unmet need with highest potential.      -- Benchmark trial results for specific drug opportunities.      -- Patient share potential for emerging therapies and target product         profiles.   -- Decision Resources proprietary analysis of commercial factors that      accelerate or constrain a drug's market potential.      -- Promotion: DTC spend, detailing intensity.      -- Reimbursement: formulary tier, prior approval restriction, quantity         limits.      -- Labeling: black box warnings, approved patient segments,         contraindications.      -- Competition: order of entry, pricing, generic entry, pipeline sales         forecast.      -- Medical practice: decision trees, treating physician type, line of         therapy.   -- Comparisons of the key clinical attributes of current and emerging      therapies in the areas of efficacy, safety, and delivery.   -- Analysis and supporting data that identifies the clinical "Gold      Standard" now and over the next ten years.   -- Key insights as to which clinical end points have the greatest      influence on physician decision-making.  

The report can be purchased by contacting Decision Resources. Members of the media may request a complimentary copy or an interview with an analyst.

About Decision Resources

Decision Resources, Inc., (www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:   Elizabeth Marshall   Decision Resources, Inc.   781-296-2563   emarshall@dresources.com 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,
+1-781-296-2563, or emarshall@dresources.com

Xenical will be Replaced by Sanofi-Aventis's Acomplia as the Clinical Gold Standard for the Treatment of Obesity by 2010

View Now